clinical development

Actinogen Medical Ltd (ACN 086 778 476) is an ASX-listed (code ACW) clinical-stage company developing Xanamem® (emestedastat), an oral therapeutic that controls levels of the stress hormone cortisol in the brain by inhibiting the 11β-HSD1 enzyme. It is developing Xanamem for Alzheimer's disease, Major Depressive Disorder, and other neurological conditions, and has conducted multiple clinical trials including a Phase 2b/3 Alzheimer's disease trial.

clinical trialsdrug development

AgeneBio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapeutics for patients at risk for neurological and psychiatric conditions, with the goal of preserving and restoring brain function. Its lead late-stage clinical program, AGB101, is being evaluated for amnestic mild cognitive impairment due to Alzheimer's disease (MCI due to AD) in the HOPE4MCI Phase 2b trial. It also has a discovery program developing GABA(A) α5 positive allosteric modulators.

Chemistry Manufacturing & Controls (CM&C) developmentdrug developmentdrug discovery

Aisa Pharma is a privately held, clinical-stage biopharmaceutical development company dedicated to bringing new disease-modifying treatments to patients with rare serious diseases. It focuses on repurposing and optimizing select calcium channel blockers, and its lead program is developing AISA-021, an oral therapy targeting N-type calcium channels for Raynaud's phenomenon associated with systemic sclerosis (scleroderma). The company is headquartered in Boston, Massachusetts, with additional presence in Sydney, Australia.

clinical operationsCMCdrug developmentRegulatory Affairsrepurposing and optimizing calcium channel blockers

Alchemab Therapeutics has developed a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires. Using well-defined patient samples, deep B cell sequencing, and computational analysis, it identifies convergent protective antibody responses among individuals resilient to specific diseases. It is building a pipeline of protective therapeutics for hard-to-treat diseases, initially focused on neurodegenerative conditions and oncology.

antibody discoveryCMCcomputational analysisdeep B cell sequencingdeep learningpre-clinical developmenttoxicology

AliquantumRx is a near-clinical infectious-disease company focused on eliminating liver-stage malaria relapse. It is developing Cethromycin HCl through its CALM (Cethromycin Against Liver-Stage Malaria) program, a short-course, G6PD testing-independent oral therapy designed to eliminate dormant liver-stage malaria and prevent relapse. The company is supported by over $6M in non-dilutive funding for IND-enabling studies and early clinical development and is pursuing human proof-of-concept and potential Priority Review Voucher eligibility.

drug developmentIND-enabling studies

Allterum Therapeutics is an early-stage biotechnology company developing precision oncology and inflammation therapeutics. Its lead program, 4A10, is an anti-CD127 monoclonal antibody targeting the CD127 pathway (IL-7 receptor complex) for relapsed leukemia, acute lymphoblastic leukemia, B-cell malignancies, lymphomas, and CD127-expressing solid tumors. The 4A10 antibody was developed at the National Cancer Institute and licensed exclusively to Fannin; Allterum is a Fannin portfolio company.

drug developmentmonoclonal antibody developmentpreclinical studiestranslational science

AN2 Therapeutics is a clinical-stage biopharmaceutical company using a boron-based discovery platform to discover and develop medicines for infectious diseases and cancer. Its pipeline includes programs in polycythemia vera, Chagas disease, M. abscessus, and oncology targets PI3K and ENPP1, with lead compound epetraborole. The company is headquartered in Menlo Park, California.

boron-based drug discovery platformdrug discovery and developmentmedicinal chemistry

Annovis Bio is a Phase 3 clinical-stage biotechnology company developing transformative therapies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Its goal is to develop effective treatments by restoring nerve cell function and improving cognitive and motor abilities in patients. The company was founded in 2008 by Dr. Maria Maccecchini and is listed on the NYSE under ANVS.

biostatisticsclinical trial operationsdrug discoveryGMP operationspilot plant productionprocess chemistry R&Dregulatory strategy and FDA submissions

Anodyne Nanotech is a clinical-stage biotech company simplifying chronic care by enabling transdermal delivery of multi-milligram doses and complex formulations of existing therapies and emerging large molecules. Its HeroPatch platform delivers clinically meaningful doses of medicine in a tunable system as an alternative to injections. The company is advancing a pipeline of transdermal biologic and peptide therapies targeting metabolic disease, endocrinology, and age-related conditions such as obesity and sarcopenia.

strategic partnershipstransdermal drug delivery

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The company leverages its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies to create therapeutic candidates designed to improve outcomes for cancer patients.

bispecific and trispecific immunotherapy developmentimmuno-oncology drug developmentpreclinical researchproprietary ADAPTIR and ADAPTIR-FLEX platforms

Aqualung Therapeutics is a clinical stage immunotherapeutics company developing targeted therapies for inflammatory injury, fibrosis, and vascular leak. Its eNamptor platform includes ALT-100, a humanized monoclonal antibody designed to neutralize eNAMPT, along with complementary biomarker tools to support precision guided treatment.

biomarker developmenttherapeutic developmenttranslational research

Aridis Pharmaceuticals, Inc. is a late-stage clinical development biopharmaceutical company focused on developing novel, differentiated therapies for infectious diseases, including first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. Its pipeline includes therapeutic monoclonal antibodies and novel anti-infectives derived from its proprietary technology platforms.

drug developmentMabIgX technology platformmonoclonal antibody discovery and development⅄PEX technology platform

Ascendis Pharma is a global biopharmaceutical company founded in 2007 and headquartered in Copenhagen, Denmark, with research facilities in Germany and offices across Europe and the United States. It applies its TransCon technology platform to develop therapies in Endocrinology Rare Disease and Oncology, and is publicly traded on Nasdaq (ASND).

biopharmaceutical research and developmentdrug innovation using TransCon technology platform

Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Its approach enables selective modulation of disease-causing proteins. The company is advancing multiple programs, including its lead asset ATV-1601, an oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT), and a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms. It has built a versatile discovery platform that identifies functional pockets across protein classes, with an internal focus on rare

allosteric drug discoverycheminformaticsCMCDMPKmedicinal chemistryRegulatory Affairstranslational research

AVEO Oncology is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. It operates as an LG Chem company, headquartered in Boston, Massachusetts, and oversees US late-stage clinical development and commercialization of anti-cancer drugs.

Biostatistics and Data Managementcommercialization of oncology therapiesmedical affairs

Bachem is a Contract Development and Manufacturing Organisation (CDMO) that develops and manufactures peptides and oligonucleotides as Active Pharmaceutical Ingredients (APIs), from early clinical development through to commercial GMP supply, for pharmaceutical and biotechnology companies worldwide. Founded in 1971, it operates four GMP-certified sites across Switzerland and the United States.

analytical capabilitiescommercial manufacturingGMP manufacturingoligonucleotide manufacturingpeptide synthesisproject managementregulatory services

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. It began working on coronavirus device and drug delivery solutions in January 2020, aiming to provide life-saving drugs to COVID-19 victims through outpatient treatment and to commercialize antivirals and delivery systems for broad global accessibility.

drug developmentlicensing and technology transfermedicinal chemistry and drug discoveryproject managementRegulatory Affairsrespiratory drug delivery

Together, we make a difference Here's to 25 years of achievements, innovation, andcollaboration. Together, we continue to make a difference for patients around the world. More on 25 years Basilea We are committed to developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with severe and life-threatening bacterial and fungal infections. Basilea is located in the Basel area, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Half-Year Report 2026 Half-year 2026 update by David Veitch David Veitch, CEO: "Our goal is to become a leading anti-infectives company and serve patients around the world." News Sep 14. 2026 Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients Read more Aug 18. 2026 / Ad hoc announcement Basilea reports strong.

commercialization of pharmaceutical productsresearch and development

BioInvent is a clinical-stage company that discovers and develops antibodies for cancer therapy. Based on expertise in immunology, cancer biology and antibody biology, it generates innovative immuno-oncology drug candidates using its proprietary F.I.R.S.T™ technology platform and n-CoDeR® antibody library. Its contract manufacturing unit, BioInvent Manufacturing, has produced drug substance for clinical trials since 1988.

antibody discovery and developmentF.I.R.S.T™ screening platformGMP manufacturingn-CoDeR® antibody librarysingle use technology

Biologics Consulting is an FDA regulatory affairs and product development consulting firm founded in 1993 by former FDA officers as a fully employee-owned (ESOP) company. It provides integrated multidisciplinary regulatory strategy and operations support for biologics, pharmaceuticals, medical devices, and combination products, with 30+ years of history, 4700+ projects, and clients in 58+ countries.

biostatistics consultationCMCFDA meeting preparationFDA submissionsnonclinical pharmacology/toxicologyquality systems & trainingregulatory operationsregulatory strategyStaff augmentation

BioVersys is an award-winning Swiss pharmaceutical company headquartered in Basel, Switzerland, focused on research and development of small molecules that work by novel modes of action and against novel targets to fight bacterial infections and antimicrobial resistance (AMR). Its pipeline includes BV100, Alpibectir, BV200, BV500 and discovery programs targeting serious hospital infections, MDR-TB, TB meningitis, S. aureus and NTM infections.

CMC strategy and operationspreclinical developmentresearch and developmentsmall molecule drug discovery

Blackfin Bio is a UK-based biotechnology spinout company from the University of Sheffield, founded in November 2023, committed to developing next-generation gene therapies. Its mission is to bring hope, healing and life-changing benefits to patients living with rare and other diseases of the Central Nervous System, including SPG47. The company aims to accelerate the clinical development of gene therapies into life-changing treatments.

gene therapy developmenttranslational research

BridgeBio Pharma, Inc. is a biotechnology company focused on developing medicines for genetic conditions. It operates a decentralized hub-and-spoke model called The Bridge Way, in which autonomous affiliate teams focus on specific conditions or drug candidates while a central hub provides clinical, regulatory, and commercial capabilities. Its pipeline includes approved products Attruby (acoramidis) and NULIBRY (fosdenopterin), plus investigational candidates such as encaleret, BBP-418, and infigratinib.

academic research partnershipsclinical trialscommercial capabilitiesdrug developmentregulatory capabilities

Cantargia AB is a Swedish listed biotechnology company that develops antibody-based therapies targeting the IL1RAP molecule for the treatment of cancer as well as inflammatory and autoimmune diseases. The company has brought two candidate drugs into clinical development, nadunolimab (CAN04) and CAN10, and develops a preclinical project CAN14 derived from its CANxx antibody platform. Cantargia was founded in 2010 by researchers Thoas Fioretos, Marcus Järås and Kjell Sjöström based on research from Lund University, and is listed on Nasdaq Stockholm's Main

antibody-based drug developmentbiomarker developmentcombination therapiesimmunotherapypreclinical research